Conference Speakers

Professor of Psychopharmacology, University of Exeter

Ketamine research and treatment

Founder, Ketamine Training Center and Ketamine Research Foundation

Ketamine-Assisted Psychotherapy

DMT Research Group, Centre for Psychedelic Research, Imperial College London

DMT and 5-MeO-DMT neuroscience

Lead Faculty, ICEERS Integration Training, Barcelona

Psychedelic integration and harm reduction

Medical Director, Axonklinikken, Oslo

Led the campaign behind Norway's national ketamine reimbursement decision

Professor of Psychiatry, Leiden University Medical Center

PTSD and trauma-focused psychedelic research

Assistant Professor, Johns Hopkins Center for Psychedelic and Consciousness Research

Psychedelics for substance use and mood disorders

PhD Candidate, Centre for Psychedelic Research, Imperial College London

DMT, 5-MeO-DMT neuroimaging, and psychedelics' effects on relationships

Clinical Researcher, MIND Foundation / OVID Clinic Berlin

The Case for Considering Psychedelics as Tools, Not Treatments

University Hospital Basel / Psychiatric University Hospital Zurich

Switzerland's compassionate-use framework for psychedelics — patient selection and ethical considerations

Senior Advisor, Veterans Health Administration

The VA's phased rollout plan for psychedelic therapy

Associate Director for Regulatory Science, U.S. Food and Drug Administration

FDA risk-mitigation (REMS) requirements for psychedelic therapies

Deputy Director of Proactive Health, ARPA-H

Ibogaine's regulatory path, described at the forum as an 'uphill battle'

Deputy Health Care Editor, POLITICO

Moderated the forum's federal-panel discussion on psychedelic access policy

Founder, Blossom

Whether European health systems can afford psychedelic therapy once approved